Effects of Length of Abstinence on Decision-making and Craving in Methamphetamine Abusers
Overview
Affiliations
Rationale: The majority of drug abusers are incapable of sustaining abstinence over any length of time. Accumulating evidence has linked intense and involuntary craving, Impulsive decision-making and mood disturbances to risk for relapse. However, little is known about temporal changes of these neuropsychological functions in methamphetamine (METH)-dependent individuals.
Objectives: To investigate the effect of length of abstinence on decision-making, craving (baseline and cue-induced), and emotional state in METH-addicted individuals.
Methods: In this cross-sectional study, 183 adult METH-dependent patients at an addiction rehabilitation center who were abstinent for 6 days (n = 37), 14 days (n = 33), 1 month (n = 31), 3 months (n = 30), 6 months (n = 26), or 1 year (n = 30) and 39 healthy subjects were administered the Iowa Gambling Task (IGT) to assess decision-making performance. Depression, anxiety, and impulsivity were also examined. One hundred thirty-nine METH abusers who were abstinent for the aforementioned times then underwent a cue session, and subjective and physiological measures were assessed.
Results: METH dependent individuals who were abstinent for longer periods of time exhibited better decision-making than those who were abstinent for shorter periods of time. And self-reported emotional symptoms improved with abstinence. METH abusers' ratings of craving decreased with the duration of abstinence, while cue-induced craving increased until 3 months of abstinence and decreased at 6 months and 1 year of abstinence.
Conclusions: We present time-dependent alterations in decision-making, emotional state, and the incubation of cue-induced craving in METH-dependent individuals, which might have significant clinical implications for the prevention of relapse.
Altshuler R, Burke M, Garcia K, Class K, Cimbro R, Li X Front Cell Neurosci. 2025; 19:1542508.
PMID: 40012565 PMC: 11860961. DOI: 10.3389/fncel.2025.1542508.
Takano A, Takahashi K, Anzai T, Usami T, Tsutsumi S, Kanazawa Y Drug Alcohol Depend Rep. 2025; 14:100316.
PMID: 39867467 PMC: 11757224. DOI: 10.1016/j.dadr.2024.100316.
Liu X, Huang Y, Mu L, Friedman V, Kelly T, Hu Y Neuropsychopharmacology. 2024; 50(4):620-629.
PMID: 39702576 PMC: 11845495. DOI: 10.1038/s41386-024-02030-x.
Leonard M, Miczek K, Covington 3rd H Psychopharmacology (Berl). 2024; 242(3):593-615.
PMID: 39511030 DOI: 10.1007/s00213-024-06711-9.
Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics.
Wolf M Annu Rev Pharmacol Toxicol. 2024; 65(1):259-280.
PMID: 39374445 PMC: 11864087. DOI: 10.1146/annurev-pharmtox-061724-080548.